These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34477531)

  • 21. Endoradiotherapy in cancer treatment--basic concepts and future trends.
    Zoller F; Eisenhut M; Haberkorn U; Mier W
    Eur J Pharmacol; 2009 Dec; 625(1-3):55-62. PubMed ID: 19836381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical animal research on therapy dosimetry with dual isotopes.
    Konijnenberg MW; de Jong M
    Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1(Suppl 1):S19-27. PubMed ID: 21484379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular tumor targeting.
    Ahlskog J; Paganelli G; Neri D
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):296-309. PubMed ID: 17043627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiation protection in therapy with radiopharmaceuticals.
    Hosono M
    Int J Radiat Biol; 2019 Oct; 95(10):1427-1430. PubMed ID: 30265162
    [No Abstract]   [Full Text] [Related]  

  • 25. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges.
    Shen RN; Lu L; Kaiser HE; Broxmeyer HE
    In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
    Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
    J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted therapy in nuclear medicine--current status and future prospects.
    Oyen WJ; Bodei L; Giammarile F; Maecke HR; Tennvall J; Luster M; Brans B
    Ann Oncol; 2007 Nov; 18(11):1782-92. PubMed ID: 17434893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The bright future of radionuclides for cancer therapy.
    Nijsen JF; Krijger GC; van Het Schip AD
    Anticancer Agents Med Chem; 2007 May; 7(3):271-90. PubMed ID: 17504155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrin α
    Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
    Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeutic advances of nuclear medicine in oncology].
    Valdés Olmos RA; Hoefnagel CA; Bais E; Boot H; Taal B; de Kraker J; Vote PA
    Rev Esp Med Nucl; 2001 Dec; 20(7):547-57. PubMed ID: 11709141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy.
    Aerts A; Impens NR; Gijs M; D'Huyvetter M; Vanmarcke H; Ponsard B; Lahoutte T; Luxen A; Baatout S
    Curr Pharm Des; 2014; 20(32):5218-44. PubMed ID: 24606796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges.
    Martins CD; Kramer-Marek G; Oyen WJG
    Expert Opin Drug Deliv; 2018 Feb; 15(2):185-196. PubMed ID: 28893110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-cancer radiopharmaceuticals.
    Hoefnagel CA
    Anticancer Drugs; 1991 Apr; 2(2):107-32. PubMed ID: 1958857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted Alpha Therapy with Thorium-227.
    Frantellizzi V; Cosma L; Brunotti G; Pani A; Spanu A; Nuvoli S; De Cristofaro F; Civitelli L; De Vincentis G
    Cancer Biother Radiopharm; 2020 Aug; 35(6):437-445. PubMed ID: 31967907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Radionuclide therapy for bone metastases: new opportunities].
    Krylov VV; Kochetova TY; Voloznev LV
    Vopr Onkol; 2015; 61(1):14-9. PubMed ID: 26016139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted alpha therapy with 213Bi.
    Morgenstern A; Bruchertseifer F; Apostolidis C
    Curr Radiopharm; 2011 Oct; 4(4):295-305. PubMed ID: 22202152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force.
    Prior JO; Gillessen S; Wirth M; Dale W; Aapro M; Oyen WJG
    Eur J Cancer; 2017 May; 77():127-139. PubMed ID: 28391026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted radionuclide therapies for pancreatic cancer.
    Shah M; Da Silva R; Gravekamp C; Libutti SK; Abraham T; Dadachova E
    Cancer Gene Ther; 2015 Aug; 22(8):375-9. PubMed ID: 26227823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.